Vestibular gland benign neoplasm

Summary

Vestibular gland benign neoplasm (MONDO:0000626) is a cancer. A subtype of vulvar benign neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	vestibular gland benign neoplasm
Mondo ID	MONDO:0000626
DOID	DOID:0060088
Anatomy (UBERON)	UBERON:0011826
Is cancer (heuristic)	yes

Also known as: vestibular gland benign neoplasm

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › benign neoplasm › benign reproductive system neoplasm › benign female reproductive system neoplasm › vulvar benign neoplasm › vestibular gland benign neoplasm

Related subtypes (7): vulvar nodular hidradenoma, vulvar syringoma, vulvar angiokeratoma, vestibular papilloma, benign mixed tumor of the vulva, vulvar trichoepithelioma, vulvar leiomyoma

Subtypes (2): Bartholin gland benign neoplasm, minor vestibular glands adenoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.